durvalumab + danvatirsen

**Durvalumab + danvatirsen** is an investigational combination therapy for cancer. - **Durvalumab** is a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to restore antitumor immune responses. - **Danvatirsen (AZD9150)** is an antisense oligonucleotide that targets signal transducer and activator of transcription 3 (**STAT3**), inhibiting its expression; STAT3 drives proliferation, survival, and immune escape in tumor cells. This combination aims to synergistically enhance antitumor activity by simultaneously releasing T-cell inhibition (via PD-L1 blockade) and disrupting cancer cell and immune microenvironment signaling (via STAT3 suppression). Clinical trials, including phase 1 studies in advanced solid tumors and diffuse large B-cell lymphoma (DLBCL), have evaluated safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The regimen is generally well tolerated, with primarily hematologic and hepatic adverse events attributed to danvatirsen; anti-tumor efficacy has been limited in early trials, though disease control and partial responses have been observed in select patients[1][2][3][5].

Brand names

Imfinzi

Other names

durvalumab + danvatirsen